168 related articles for article (PubMed ID: 23743853)
21. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
22. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
23. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.
Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S
Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
27. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
28. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic γ Herpesviruses EBV and HHV8 in Kidney Transplantation.
Le J
Semin Nephrol; 2016 Sep; 36(5):362-371. PubMed ID: 27772621
[TBL] [Abstract][Full Text] [Related]
30. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
31. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
32. Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.
Valencia-Sanchez C; Steenerson KK; Kelemen K; Orenstein R; Kusne S; Grill MF
J Neurovirol; 2019 Apr; 25(2):280-283. PubMed ID: 30607891
[TBL] [Abstract][Full Text] [Related]
33. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
34. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
35. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW
Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous Manifestations of Posttransplant Lymphoma in Renal Transplant Recipients: A Case Series.
Patil R; Prashar R; Patel A
Transplant Proc; 2021 Jun; 53(5):1519-1527. PubMed ID: 34134932
[TBL] [Abstract][Full Text] [Related]
38. Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report.
Tanaka H; Matsuda R; Nakamura M; Nakagawa I; Nakase H
Anticancer Res; 2022 Aug; 42(8):3975-3979. PubMed ID: 35896237
[TBL] [Abstract][Full Text] [Related]
39. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
Bitzan M; Ouahed JD; Carpineta L; Bernard C; Bell LE
Pediatr Nephrol; 2010 Jun; 25(6):1163-7. PubMed ID: 20140460
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
